-
公开(公告)号:US20050080110A1
公开(公告)日:2005-04-14
申请号:US10486867
申请日:2002-08-06
申请人: Daniel Sall , Jolie Bastian , Rushad Karanjawala , Cynthia Jesudason , Theo Schotten , Britta Evers , Gerd Reuhter , Don Finley , Freddie Stevens , Vincent Rocco , Patrick Spinazze , John He , John Werner , William Trankle , Andrew Ratz
发明人: Daniel Sall , Jolie Bastian , Rushad Karanjawala , Cynthia Jesudason , Theo Schotten , Britta Evers , Gerd Reuhter , Don Finley , Freddie Stevens , Vincent Rocco , Patrick Spinazze , John He , John Werner , William Trankle , Andrew Ratz
IPC分类号: A61K31/381 , A61K31/4045 , A61K31/41 , A61K31/4178 , A61K31/4196 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/427 , A61K31/433 , A61K31/4436 , A61K31/4439 , A61K31/506 , A61P3/04 , A61P3/10 , A61P43/00 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D49/02 , C07D41/02 , C07D43/02
CPC分类号: C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要: The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity.
摘要翻译: 本发明涉及式(I)的β3肾上腺素能受体激动剂; 或其药学盐; 其能够增加细胞中的脂肪分解和能量消耗,因此可用于例如治疗2型糖尿病和/或肥胖症。
-
公开(公告)号:US20050159473A1
公开(公告)日:2005-07-21
申请号:US11082106
申请日:2005-03-16
申请人: Daniel Sall , Jolie Bastian , Cynthia Jesudason , Don Finley , Freddie Stevens , Vincent Rocco , Patrick Spinazze , John He , John Werner , William Trankle , Andrew Ratz , Theo Schotten , Gerd Reuhter
发明人: Daniel Sall , Jolie Bastian , Cynthia Jesudason , Don Finley , Freddie Stevens , Vincent Rocco , Patrick Spinazze , John He , John Werner , William Trankle , Andrew Ratz , Theo Schotten , Gerd Reuhter
IPC分类号: A01N41/12 , A61K31/4045 , A61K31/4178 , A61K31/4196 , A61K31/427 , A61K31/4439 , A61K31/497 , A61P3/04 , A61P3/10 , C07D209/34 , C07D209/96 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/14 , C07D521/00 , A61K31/404 , C07D43/02
CPC分类号: C07D231/12 , C07D209/34 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/14
摘要: The present invention relates to a β3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
摘要翻译: 本发明涉及式I的β3肾上腺素能受体激动剂:或其药用盐; 其能够增加细胞中的脂肪分解和能量消耗,因此可用于治疗2型糖尿病和/或肥胖症。
-
公开(公告)号:US20060084643A1
公开(公告)日:2006-04-20
申请号:US10523147
申请日:2003-07-28
申请人: Thomas Aicher , Zhaogen Chen , Yvan Lehuerou , Fionna Martin , Marta Pineiro-Nunez , Vincent Rocco , Kevin Ruley , John Schaus , Patrick Spinazze , David Tupper
发明人: Thomas Aicher , Zhaogen Chen , Yvan Lehuerou , Fionna Martin , Marta Pineiro-Nunez , Vincent Rocco , Kevin Ruley , John Schaus , Patrick Spinazze , David Tupper
IPC分类号: A61K31/551 , C07D498/02
CPC分类号: C07D403/04 , C07D495/04 , C07D513/04
摘要: Described herein are compounds of formula (I) use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treament of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).
摘要翻译: 本文描述的式(I)化合物是式(I)化合物用作多巴胺D2受体的拮抗剂并用作精神病和双相性精神障碍的药剂,以及式(I)化合物的药物制剂。
-
-